Haemonetics HAE
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Haemonetics (HAE) Business Model and Operations Summary
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Key Insights
Haemonetics (HAE) Core Market Data and Business Metrics
Latest Closing Price
$63.02Market Cap
$3.16 BillionPrice-Earnings Ratio
26.15Total Outstanding Shares
50.24 Million SharesTotal Employees
3,657Dividend
No dividendIPO Date
May 9, 1991SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
New York Stock ExchangeHeadquarters
125 Summer Street, Boston, MA, 02110
Historical Stock Splits
If you bought 1 share of HAE before December 3, 2012, you'd have 2 shares today.
| Execution Date | Split Amount |
|---|---|
| December 3, 2012 | 2-for-1 |
Cash Flow Statement
September 29, 2023 to September 28, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-444.56 Million |
| Net Cash Flow | $-51.72 Million |
| Net Cash Flow, Continuing | $-54.80 Million |
| Net Cash Flow From Operating Activities | $84.94 Million |
| Net Cash Flow From Financing Activities | $304.81 Million |
| Net Cash Flow From Investing Activities | $-444.56 Million |
Income Statement
September 29, 2023 to September 28, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $0 |
| Diluted Earnings Per Share | $2.41 |
| Basic Average Shares | $101.72 Million |
| Selling, General, and Administrative Expenses | $448.59 Million |
| Cost Of Revenue | $645.09 Million |
| Benefits Costs and Expenses | $1.20 Billion |
Comprehensive Income
September 29, 2023 to September 28, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $121.95 Million |
| Other Comprehensive Income/Loss | $-1.86 Million |
| Comprehensive Income/Loss | $121.95 Million |
Balance Sheet
September 29, 2023 to September 28, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $1.37 Billion |
| Other Current Assets | $573.80 Million |
| Equity Attributable To Parent | $878.85 Million |
| Other Non-current Assets | $781.01 Million |
| Assets | $2.53 Billion |
| Current Liabilities | $273.95 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||